Retinitis pigmentosa: recent advances and future directions in diagnosis and management
Abstract
Retinitis pigmentosa is a group of genetically diverse inherited blinding disorders for which there are no treatments. Owing to recent advances in imaging technology, DNA sequencing, gene therapy, and stem cell biology, clinical trials have multiplied and the landscape is rapidly changing. This review provides a relevant and timely update of current trends and future directions for the diagnosis and management of this disease. This review will highlight the use of retinal imaging to measure progression of disease, next-generation sequencing for genetic diagnosis, the use of electronic retinal implants as well as noninvasive digital low-vision aids, and the current state of preclinical and clinical research with gene therapy and cell-based therapies. Retinitis pigmentosa has historically been an untreatable condition. Recent advances have allowed for limited improvement in visual outcomes for select patients. Retinal degenerative disease is on the cutting edge of regenerative medicine. Gene therapy and stem cell therapeutic strategies are currently under investigation and are expected to radically impact management of inherited retinal disease in the coming years. VIDEO ABSTRACT: http://links.lww.com/MOP/A33.
References
The known unknown: the challenges of genetic variants of uncertain significance in clinical practice
Citations
Associations Between Fundus Types and Clinical Manifestations in Patients with RDH12 Gene Mutations.
Related Concepts
Related Feeds
CREs: Gene & Cell Therapy
Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.
Allogenic & Autologous Therapies
Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.